Insmed Inc (INSM)vsIterum Therapeutics PLC (ITRM)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
ITRM
Iterum Therapeutics PLC
$0.17
-1.35%
HEALTHCARE · Cap: $8.60M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 155393% more annual revenue ($606.42M vs $390,000). ITRM leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
ITRM
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -5.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : ITRM
ITRM has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : ITRM
The primary concerns for ITRM are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while ITRM is a value play — different risk/reward profiles.
ITRM carries more volatility with a beta of 3.01 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ITRM generates stronger free cash flow (-8M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Iterum Therapeutics PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, is engaged in the development of anti-infectives for multidrug resistant pathogens in Ireland and the United States. The company is headquartered in Dublin, Ireland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?